23andMe’s MAP Report Receives FDA’s 510(k) Clearance for Hereditary Colorectal Cancers

 23andMe’s MAP Report Receives FDA’s 510(k) Clearance for Hereditary Colorectal Cancers

23andMe’s MAP Report Receives FDA’s 510(k) Clearance for Hereditary Colorectal Cancers

  Shots:

  • MAP Report is a direct-to-consumer genetic test and has received FDA approval for MUTYH-associated polyposis (MAP), a hereditary colorectal cancer syndrome
  • Post-FDA approval for BRCA1/BRCA2 (Selected Variants) Genetic Health Risk report in Mar 2018, 23andMe has received its second FDA approval for MAP Report detecting two variants in people with MAP
  • The approval allows patients for genetic testing with accurate results & is available for patients with educational module choosing to view their MAP report

Click here to read full press release/ article | Ref: 23andMe | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post